ESMO 2019: MONALEESA-3 Update Demonstrates Activity of Ribociclib for Breast Cancer in Postmenopausal Setting
Benefits now seen in pre- and postmenopausal setting with hormone receptor-positive, HER2-negative disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.